SCD1 deficiency in mice reduces lipid synthesis and increases mitochondrial fatty acid β-oxidation and insulin sensitivity in several tissues including the liver and prevents hepatic steatosis in mouse models of NASH9,11; these data point to SCD1 as a potential therapeutic target in NASH. This evidence concerns the gene SCD and metabolic dysfunction-associated steatohepatitis.